RecallRadar

FDA Drug recall D-0649-2021

Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc

On 2021-07-14 the FDA classified a Class II recall of Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc by Alvogen, citing subpotent drug: Out of specification for assay of naloxone and buprenorphine (low).

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0649-2021
ClassificationClass II
Statusterminated
Initiated2021-02-26
Published2021-07-14
Last updated2026-09-13 11:52 UTC
CompanyAlvogen
DistributionUS

Product

Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA, NDC 47781-355-03

Reason

Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)

Identifiers

ndc47781-355-11
ndc47781-355-03
ndc47781-356-11
ndc47781-356-03
ndc47781-357-11
ndc47781-357-03
ndc47781-358-11
ndc47781-358-03
code_infoLot #: 36924, Exp 6/2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0649-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.